← brief for 2026-09-09 · Slowing decline

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network.

Key takeaways

Fabry disease is a rare inherited illness that damages the kidneys and the heart, and there is very little research on which drugs help. This study used a large global network of patient records to see whether SGLT2 inhibitors, pills that protect kidneys in diabetes and heart failure, were linked to fewer heart events here too. It included adults with a kidney filtering rate (eGFR) of 20 or above. Because it draws on records rather than a trial, it shows a link and not proof of cause.

Who did this work

Serio L · Rossi M · Askarinejad A · Tartaglia E · Bucci T · Marrone E · Kalra DK · Ferri C · Lip GYH

Source

Article · PubMed, the drug frontier · 2026 Sep 8
https://pubmed.ncbi.nlm.nih.gov/42712107/